ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Aug 15, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-08-13

Reporting Person: Dorsey Brian (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-13	Common Stock	M	30000	$0.64	Acquired	36024	Direct
2024-08-13	Common Stock	S	30000	$13	Disposed	6024	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-13	Stock Option (Right to Buy)	$0.64	M	30000	Disposed	2028-11-28	Common Stock (30000)	Direct

Footnotes

F1: Includes 2,159 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,013 shares acquired under the ESPP on December 29, 2023 and 2,852 shares acquired under the ESPP on June 29, 2024.

F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.

F3: Immediately exercisable.